Literature DB >> 11075653

Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand.

V Bussaratid1, D S Walsh, P Wilairatana, S Krudsood, U Silachamroon, S Looareesuwan.   

Abstract

Chloroquine-induced itch in black-skinned African malaria patients is common and frequently leads to poor compliance or treatment defaulting.To assess the frequency and severity of chloroquine-induced pruritus in an Asian population, we reviewed case records of 1189 Plasmodium vivax malaria patients treated with chloroquine (25 mg/kg over 3 days) at the Bangkok Hospital for Tropical Diseases from 1992 through 1997. The majority of patients were Thais or ethnic Burmese (light brown skin), referred from the western border of Thailand. Overall, there were 23 patients (1.9%) with complaints of pruritus during chloroquine therapy. Of these, 12 (52%) had palm and sole involvement, eight (35%) had generalized pruritus including the palms and soles, and three (13%) had palm itching only. One patient developed pruritus on the palms and soles on two consecutive admissions. The pruritus did not interfere with daily activity, was reduced in intensity by anti-histamine therapy, and did not affect the patient's willingness to complete the chloroquine regimen. Therapeutic responses in the 23 patients with chloroquine itch was similar to those without itch. Among the itch patients, there was no association with gender or level of parasitaemias. Our findings indicate that the frequency of chloroquine-induced pruritus in Asian patients treated with chloroquine for P. vivax malaria is low in comparison with black-skinned Africans.This may be related to pharmacogenetic factors, the infective Plasmodium species, drug metabolism or drug-parasite interactions, or a lower affinity of chloroquine for less pigmented skin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11075653     DOI: 10.1177/004947550003000410

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  8 in total

Review 1.  Mouse models of acute, chemical itch and pain in humans.

Authors:  Robert H LaMotte; Steven G Shimada; Parul Sikand
Journal:  Exp Dermatol       Date:  2011-10       Impact factor: 3.960

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 3.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Chloroquine-induced Pruritus.

Authors:  S E Aghahowa; H O Obianwu; A O Isah; I M Arhewoh
Journal:  Indian J Pharm Sci       Date:  2010-05       Impact factor: 0.975

Review 5.  Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature.

Authors:  Marcus V G Lacerda; Maria P G Mourão; Márcia A A Alexandre; André M Siqueira; Belisa M L Magalhães; Flor E Martinez-Espinosa; Franklin S Santana Filho; Patrícia Brasil; Ana M R S Ventura; Mauro S Tada; Vanja S C D Couto; Antônio R Silva; Rita S U Silva; Maria G C Alecrim
Journal:  Malar J       Date:  2012-01-09       Impact factor: 2.979

6.  Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.

Authors:  Issaka Sagara; Abraham R Oduro; Modest Mulenga; Yemou Dieng; Bernhards Ogutu; Alfred B Tiono; Peter Mugyenyi; Ali Sie; Monique Wasunna; Kevin C Kain; Abdoulaye A Djimdé; Shirsendu Sarkar; Richa Chandra; Jeffery Robbins; Michael W Dunne
Journal:  Malar J       Date:  2014-11-25       Impact factor: 2.979

7.  Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.

Authors:  Lilia Gonzalez-Ceron; Mario H Rodriguez; Marco A Sandoval; Frida Santillan; Sonia Galindo-Virgen; Angel F Betanzos; Angel F Rosales; Olga L Palomeque
Journal:  Malar J       Date:  2015-10-30       Impact factor: 2.979

Review 8.  Non-dermatological Challenges of Chronic Itch.

Authors:  Andreas E Kremer; Thomas Mettang; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.